
In the BEST-CLI study, published in The New England Journal of Medicine, researchers compared endovascular therapy with surgical revascularization for improving limb outcomes in patients with chronic limb-threating ischemia, an advanced stage of peripheral arterial disease (PAD).
According to the study’s lead author, Alik Farber, major adverse events and deaths were significantly reduced with surgical revascularization versus endovascular therapy among patients who had a section of great saphenous vein that was viable for surgery (cohort 1); However, in patients who did not have a viable vein and required an alternative bypass conduit (cohort 2), the two interventions had similar outcomes.
The BEST-CLI study enrolled 1830 patients with CLTI and infrainguinal PAD in 2 international parallel-cohort trials. The primary end point was a composite of major adverse events requiring amputation above the ankle, major limb reinterventions, and any-cause mortality.